Is STEX or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Biosig Technologies' net margin of 0.00%. Nephros' return on equity of 7.66% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Biosig Technologies N/A -717.92% -336.75% Nephros 4.06% 7.66% 5.86%

Does the media prefer STEX or NEPH?

In the previous week, Biosig Technologies and Biosig Technologies both had 3 articles in the media. Biosig Technologies' average media sentiment score of 0.81 beat Nephros' score of 0.79 indicating that Biosig Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nephros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, NEPH or GUTS?

Nephros has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $18.79M 2.18 $1.19M $0.07 54.00 Fractyl Health $90K 1,427.85 -$140.95M -$1.29 N/A

Is NEPH or GUTS more profitable?

Nephros has a net margin of 4.06% compared to Fractyl Health's net margin of 0.00%. Nephros' return on equity of 7.66% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Fractyl Health N/A -4,053.15% -96.41%

Does the media prefer NEPH or GUTS?

In the previous week, Fractyl Health had 2 more articles in the media than Nephros. MarketBeat recorded 5 mentions for Fractyl Health and 3 mentions for Nephros. Nephros' average media sentiment score of 0.79 beat Fractyl Health's score of 0.52 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fractyl Health 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, NEPH or CVRX?

Nephros has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $18.79M 2.18 $1.19M $0.07 54.00 CVRx $56.65M 2.30 -$53.31M -$2.02 N/A

Is NEPH or CVRX more profitable?

Nephros has a net margin of 4.06% compared to CVRx's net margin of -89.14%. Nephros' return on equity of 7.66% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% CVRx -89.14% -120.76% -48.38%

Does the media favor NEPH or CVRX?

In the previous week, Nephros had 2 more articles in the media than CVRx. MarketBeat recorded 3 mentions for Nephros and 1 mentions for CVRx. Nephros' average media sentiment score of 0.79 beat CVRx's score of 0.00 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CVRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NEPH or RCEL more profitable?

Nephros has a net margin of 4.06% compared to Avita Medical's net margin of -62.67%. Nephros' return on equity of 7.66% beat Avita Medical's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Avita Medical -62.67% N/A -78.92%

Does the media prefer NEPH or RCEL?

In the previous week, Nephros had 1 more articles in the media than Avita Medical. MarketBeat recorded 3 mentions for Nephros and 2 mentions for Avita Medical. Nephros' average media sentiment score of 0.79 beat Avita Medical's score of 0.57 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avita Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NEPH or STIM more profitable?

Nephros has a net margin of 4.06% compared to Neuronetics' net margin of -24.48%. Nephros' return on equity of 7.66% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Neuronetics -24.48% -139.83% -27.13%

Does the media prefer NEPH or STIM?

In the previous week, Nephros and Nephros both had 3 articles in the media. Nephros' average media sentiment score of 0.79 beat Neuronetics' score of 0.33 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nephros (NEPH) Competitors

$3.78 +0.02 (+0.53%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$3.72 -0.06 (-1.59%)

As of 07/17/2026 04:10 PM Eastern

Compare

NEPH vs. STEX, GUTS, CVRX, RCEL, and STIM

Should you buy Nephros stock or one of its competitors? MarketBeat compares Nephros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nephros include Biosig Technologies (STEX), Fractyl Health (GUTS), CVRx (CVRX), Avita Medical (RCEL), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.

How does Nephros compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and Nephros (NASDAQ:NEPH) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Biosig Technologies presently has a consensus target price of $8.00, indicating a potential upside of 921.45%. Nephros has a consensus target price of $5.00, indicating a potential upside of 32.28%. Given Biosig Technologies' higher possible upside, analysts plainly believe Biosig Technologies is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nephros	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biosig Technologies has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, Nephros has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Nephros has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,559.64	-$462.77M	-$9.71	N/A
Nephros	$18.79M	2.18	$1.19M	$0.07	54.00

Nephros has a net margin of 4.06% compared to Biosig Technologies' net margin of 0.00%. Nephros' return on equity of 7.66% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Nephros	4.06%	7.66%	5.86%

In the previous week, Biosig Technologies and Biosig Technologies both had 3 articles in the media. Biosig Technologies' average media sentiment score of 0.81 beat Nephros' score of 0.79 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nephros beats Biosig Technologies on 9 of the 14 factors compared between the two stocks.

How does Nephros compare to Fractyl Health?

Nephros (NASDAQ:NEPH) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Nephros has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.18	$1.19M	$0.07	54.00
Fractyl Health	$90K	1,427.85	-$140.95M	-$1.29	N/A

Nephros has a net margin of 4.06% compared to Fractyl Health's net margin of 0.00%. Nephros' return on equity of 7.66% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Fractyl Health	N/A	-4,053.15%	-96.41%

Nephros presently has a consensus price target of $5.00, indicating a potential upside of 32.28%. Fractyl Health has a consensus price target of $5.12, indicating a potential upside of 532.10%. Given Fractyl Health's stronger consensus rating and higher probable upside, analysts clearly believe Fractyl Health is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nephros has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

41.1% of Nephros shares are held by institutional investors. 6.7% of Nephros shares are held by company insiders. Comparatively, 8.5% of Fractyl Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Fractyl Health had 2 more articles in the media than Nephros. MarketBeat recorded 5 mentions for Fractyl Health and 3 mentions for Nephros. Nephros' average media sentiment score of 0.79 beat Fractyl Health's score of 0.52 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fractyl Health	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nephros beats Fractyl Health on 9 of the 16 factors compared between the two stocks.

How does Nephros compare to CVRx?

Nephros (NASDAQ:NEPH) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Nephros has a net margin of 4.06% compared to CVRx's net margin of -89.14%. Nephros' return on equity of 7.66% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
CVRx	-89.14%	-120.76%	-48.38%

Nephros has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.18	$1.19M	$0.07	54.00
CVRx	$56.65M	2.30	-$53.31M	-$2.02	N/A

Nephros has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, CVRx has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

In the previous week, Nephros had 2 more articles in the media than CVRx. MarketBeat recorded 3 mentions for Nephros and 1 mentions for CVRx. Nephros' average media sentiment score of 0.79 beat CVRx's score of 0.00 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nephros presently has a consensus target price of $5.00, suggesting a potential upside of 32.28%. CVRx has a consensus target price of $11.50, suggesting a potential upside of 134.22%. Given CVRx's stronger consensus rating and higher probable upside, analysts plainly believe CVRx is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

41.1% of Nephros shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 13.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Nephros beats CVRx on 9 of the 16 factors compared between the two stocks.

How does Nephros compare to Avita Medical?

Nephros (NASDAQ:NEPH) and Avita Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Nephros has a net margin of 4.06% compared to Avita Medical's net margin of -62.67%. Nephros' return on equity of 7.66% beat Avita Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Avita Medical	-62.67%	N/A	-78.92%

41.1% of Nephros shares are owned by institutional investors. Comparatively, 27.7% of Avita Medical shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 2.2% of Avita Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nephros presently has a consensus price target of $5.00, indicating a potential upside of 32.28%. Avita Medical has a consensus price target of $7.25, indicating a potential upside of 42.16%. Given Avita Medical's stronger consensus rating and higher possible upside, analysts plainly believe Avita Medical is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Avita Medical	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Nephros had 1 more articles in the media than Avita Medical. MarketBeat recorded 3 mentions for Nephros and 2 mentions for Avita Medical. Nephros' average media sentiment score of 0.79 beat Avita Medical's score of 0.57 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avita Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nephros has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Avita Medical has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

Nephros has higher earnings, but lower revenue than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.18	$1.19M	$0.07	54.00
Avita Medical	$71.61M	2.19	-$48.59M	-$1.57	N/A

Summary

Nephros beats Avita Medical on 10 of the 16 factors compared between the two stocks.

How does Nephros compare to Neuronetics?

Nephros (NASDAQ:NEPH) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Nephros has a net margin of 4.06% compared to Neuronetics' net margin of -24.48%. Nephros' return on equity of 7.66% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Neuronetics	-24.48%	-139.83%	-27.13%

Nephros has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Neuronetics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

In the previous week, Nephros and Nephros both had 3 articles in the media. Nephros' average media sentiment score of 0.79 beat Neuronetics' score of 0.33 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.1% of Nephros shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 8.4% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Nephros currently has a consensus target price of $5.00, suggesting a potential upside of 32.28%. Neuronetics has a consensus target price of $3.00, suggesting a potential upside of 85.19%. Given Neuronetics' higher possible upside, analysts clearly believe Neuronetics is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nephros has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.18	$1.19M	$0.07	54.00
Neuronetics	$149.16M	0.76	-$39M	-$0.54	N/A

Summary

Nephros beats Neuronetics on 10 of the 14 factors compared between the two stocks.

Get Nephros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEPH vs. The Competition

Export

Metric	Nephros	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.04M	$8.81B	$6.88B	$12.29B
Dividend Yield	N/A	2.47%	2.67%	9.34%
P/E Ratio	54.01	16.06	27.25	23.90
Price / Sales	2.18	6.87	516.34	85.22
Price / Cash	30.13	18.26	52.99	60.41
Price / Book	3.94	3.28	10.69	6.18
Net Income	$1.19M	$228.19M	$3.59B	$332.29M
7 Day Performance	4.13%	-2.43%	-2.20%	-2.05%
1 Month Performance	20.00%	-1.02%	1.63%	-2.15%
1 Year Performance	3.85%	0.14%	25.59%	17.26%

Nephros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEPH Nephros	2.4296 of 5 stars	$3.78 +0.5%	$5.00 +32.3%	+5.6%	$41.04M	$18.79M	54.01	30	Analyst Forecast Gap Up
STEX Biosig Technologies	3.2894 of 5 stars	$0.82 -0.4%	$8.00 +870.9%	N/A	$149.62M	$40K	N/A	50	News Coverage Analyst Downgrade Buyback Announcement
GUTS Fractyl Health	4.1984 of 5 stars	$0.89 +10.8%	$5.12 +477.9%	-54.7%	$139.77M	$90K	N/A	102
CVRX CVRx	1.5635 of 5 stars	$5.21 +0.9%	$11.50 +120.8%	-41.2%	$138.11M	$56.65M	N/A	160
RCEL Avita Medical	3.8157 of 5 stars	$4.21 +4.8%	$7.25 +72.1%	-6.1%	$129.43M	$71.61M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEPH) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nephros (NEPH) Competitors

NEPH vs. STEX, GUTS, CVRX, RCEL, and STIM

How does Nephros compare to Biosig Technologies?

Summary

How does Nephros compare to Fractyl Health?

Summary

How does Nephros compare to CVRx?

Summary

How does Nephros compare to Avita Medical?

Summary

How does Nephros compare to Neuronetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nephros (NEPH) Competitors

NEPH vs. STEX, GUTS, CVRX, RCEL, and STIM

How does Nephros compare to Biosig Technologies?

Do analysts recommend STEX or NEPH?

Do institutionals & insiders believe in STEX or NEPH?

Which has more risk and volatility, STEX or NEPH?

Which has preferable earnings & valuation, STEX or NEPH?

Is STEX or NEPH more profitable?

Does the media prefer STEX or NEPH?

Summary

How does Nephros compare to Fractyl Health?

Which has better earnings & valuation, NEPH or GUTS?

Is NEPH or GUTS more profitable?

Do analysts recommend NEPH or GUTS?

Which has more volatility and risk, NEPH or GUTS?

Do insiders & institutionals believe in NEPH or GUTS?

Does the media prefer NEPH or GUTS?

Summary

How does Nephros compare to CVRx?

Is NEPH or CVRX more profitable?

Which has preferable valuation and earnings, NEPH or CVRX?

Which has more volatility & risk, NEPH or CVRX?

Does the media favor NEPH or CVRX?

Do analysts prefer NEPH or CVRX?

Do institutionals & insiders hold more shares of NEPH or CVRX?

Summary

How does Nephros compare to Avita Medical?

Is NEPH or RCEL more profitable?

Do institutionals and insiders believe in NEPH or RCEL?

Do analysts prefer NEPH or RCEL?

Does the media prefer NEPH or RCEL?

Which has more risk & volatility, NEPH or RCEL?

Which has preferable earnings and valuation, NEPH or RCEL?

Summary

How does Nephros compare to Neuronetics?

Is NEPH or STIM more profitable?

Which has more volatility & risk, NEPH or STIM?

Does the media prefer NEPH or STIM?

Do insiders & institutionals have more ownership in NEPH or STIM?

Do analysts rate NEPH or STIM?

Which has better earnings and valuation, NEPH or STIM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools